IPCURE

About Us

IPcure brings innovation in neurology and inflammation disorders by targeting individual caspases to develop solutions that address neuro-degenerative, inflammatory, and metabolic diseases. Our flagship drug candidate targets Caspase-2, a crucial enzyme in memory function, aiming to revolutionize the treatment of Frontotemporal Dementia (FTD) and Alzheimer's Disease (AD). Our ultimate goal is to provide innovative, effective treatments that pave the way toward the cure of these debilitating conditions, enhancing the quality of life for patients worldwide.

KEY PUBLICATIONS

NEW!!Caspase-2 kills cells with extra centrosomes Rizzotto et al., Sci. Adv. 10, eado6607 (2024) 30 October 2024 (Impact Factor 14.136)
Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice Pozueta et al. NATURE COMMUNICATIONS | 4:1939 | DOI: 10.1038/ncomms2927 (Impact Factor 14.7)

Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitorChauvier et al. Cell Death and Disease (2011) (Impact Factor 8.1)
(…)

RECENTS POST

Available Now: New Tools for Caspase 2 Reseach
Venture Summit West, Silicon Valley
Frontotemporal dementia (FTD)
Frontotemporal disease : Behavioral changes

QUICK MENU